COVID-19 and childhood asthma: Analysis of a pediatric referral hospital

To the Editor,

Spain has been one of the epicenters of the SARS-CoV-2 pandemic. Children (0–14 years-old) account for at least 10.5% of all cases and usually develop mild severity of coronavirus disease 2019 (COVID-19). Clinical observations point out allergy and/or asthma are not risky conditions in pediatric patients with COVID-19, and hypothetically, allergic sensitization could be inversely related to the expression of COVID-19. However, little is known about the effect of SARS-CoV-2 infection in allergic and/or asthmatic children and adolescents.

This study, approved by the Ethics Committee of Hospital Niño Jesús (Madrid, Spain), aimed to evaluate allergic comorbidities among symptomatic COVID-19 children attended at a referral pediatric hospital for this disease. The database of positive SARS-CoV-2 cases diagnosed based on reverse transcription polymerase chain reaction (RT-PCR) between 20 March and 13 July 2020 was retrospectively reviewed. Demographic information, COVID-19 symptoms, disease severity, clinical course, comorbidities, and blood biomarkers were obtained from electronic medical records. Eosinopenia was defined as absolute eosinophil counts ≤0.05 × 10⁹ cells/L. Information on allergic disorders was obtained by telephone interview with parents and patients, who provided their oral consent to participate. The severity of COVID-19 was established according to Qiu’s classification. The criteria used to classify as allergic or asthmatic patients included a specialized physician’s diagnosis. A modified questionnaire on allergy and asthma based on a survey from the Asthma Committee of the Spanish Society of Allergy and Clinical Immunology was used.

Qualitative variables are expressed as numbers and percentages, and the Fisher and chi-squared tests were used for comparison. Quantitative variables are expressed as mean and standard deviation (SD) or median and interquartile range (IQR) according to their distribution. Normality of age distribution was confirmed using the Shapiro–Wilk test. The Student T, ANOVA, and least significant difference (LSD) tests were used as post hoc tests to compare normally distributed variables. The Wilcoxon, Mann–Whitney U, and Kruskal–Wallis tests were used to compare nonparametric variables. Statistical significance was set at 95% (p < .05).

Ninety-two children were identified as SARS-CoV-2-RT-PCR positive, two declined to participate. Asymptomatic patients were excluded. Fifty patients were diagnosed with symptomatic COVID-19 disease (52% male; mean age: 7 ± 7 years, IQR: 6 months–12 years) and finally enrolled (Figure 1). Regarding the severity, 37(74%) had mild-moderate COVID. The remainder developed a severe disease.

Demographics and clinical features of asthmatic and nonasthmatic children with symptomatic COVID-19 were collected (Table 1). Eight of 50 symptomatic children had asthma with or without RC (Figure 1 and Table 2). Asthmatic patients (8/50; 16%) developed more respiratory symptoms caused by COVID-19 than nonasthmatic patients (42/50; 84%) (p = .018). No statistical difference was found for fever, anosmia, ageusia, gastrointestinal or cutaneous symptoms, COVID severity, discharged, hospitalization or PICU admission.

Regarding asthma control based on GINA guidelines, 75% had well-controlled asthma, 25% partially controlled, 37.5% had a mild exacerbation due to COVID-19 disease, and only 37.5% needed to escalate controller treatment (Table 2).

According to supplementary tests, all asthmatic patients had a chest x-ray done and six (75%) had a blood test performed (Tables 1 and 2). No statistical difference was found comparing both groups regarding imaging test. However, laboratory tests demonstrated a significant eosinopenia in the asthmatic group (p = .014) as well as comparing the number of eosinophils in each group (p = .008). Moreover, the condition of eosinopenia and the total number of eosinophils was related to the severity of the disease (respectively, p = .005 and p = .013). Showing that in moderate and severe disease, eosinophils were lower than in patients with milder disease (three patients had a blood test analysis done with mild disease: median 960 (IQR: 130–960) cells/µL, 21 patients with moderate disease: median 170 (IQR: 70–320) cells/µL, and 13 patients had severe disease: median 40 (IQR: 25–105) cells/µL). A month later during the follow-up, eosinopenia was recovered in nine (81.8%) patients, and it was significantly higher in the nonasthmatic group (p = .007; Table 1).

Regarding evolution, three (37.5%) asthmatic patients remained with exercise-induced asthma; the remainder did not present any immediate sequelae at the time of writing this paper. None of the patients had issues to get access to medication or medical care during the pandemic.

At the current stage of knowledge, children develop less severe symptoms of COVID-19, although the concern about the importance of underlying respiratory diseases, such as asthma, is still widely spread. Furthermore, it has been studied whether severe asthma should be classified as a risk factor. In our study, we found that 16% of the patients were asthmatic. These patients had more respiratory symptoms due to COVID-19.
Comparing them with nonasthmatic patients, we could not find any other statistical difference regarding other variables, but this may be due to a reduce statistical power. However, the asthmatic group developed more eosinopenia, which was correlated with severity of the disease and also showed that recovery was lower compared to that of the nonasthmatic group.

The prevalence of allergy and asthma in this cohort was 26% higher than that in other series published to date. The age of our population, similar to the studies previously mentioned, might play a part to this issue as normally younger patients have allergic asthma and other allergic comorbidities.

Papadopoulos et al. published similar data in a multicenter study in regards to asthma control. However, in their results, 10% of the asthmatic population studied needed to increase their controller treatment.

Our data showed that 76% of the total patients had mild-moderate COVID-19 disease. Similar findings have been published by the studies conducted in children. To our knowledge, this is the first study reporting comparisons between asthmatic and nonasthmatic pediatric patients with alterations in the chest x-ray. Literature is scarce on this topic as the major study performed in children used CT scan. An Italian group showed 10% of patients with pneumonia, but neither this study nor others specify if these patients were asthmatic.

Similar limitations are observed in the analysis of blood eosinophils. Eosinopenia is known to be a severity predictor in COVID-19 disease. In our cohort, asthmatic patients developed more eosinopenia and their recovery was lower compared to that of the nonasthmatic group. To date, no other studies have published similar data, and no relationship has access between COVID-19 disease, asthma, and eosinopenia. However, our results are conditioned on the number of participants enrolled, not all were followed before in our center, nor had a recent blood test done, so we could not compare whether this condition was previously ongoing, and it should be taken into account that moderate-severe forms of COVID-19 are more prone to have a blood test done.

Recovery was full in all patients, as other studies have published. Although, 37.5% of our asthmatic patients remained with exercise exacerbated asthma after COVID-19 disease. Pulmonary function tests were not performed afterwards, leading to limited information on the baseline pulmonary capacity in our population. Furthermore, despite being standardized tools, these could not be performed due to the risk of generating aerosols.

Our study has limitations due to its retrospective nature and the age of the participants enrolled, which at the time this study was conducted, little was known about COVID-19 in this age group.

In summary, to our knowledge, this is the first report describing asthma and other allergic comorbidities in children with confirmed COVID-19 disease. In our study, asthma has a low prevalence among COVID-19 pediatric patients with some differences related to their clinical manifestations of their disease and laboratory findings. Nevertheless, more studies are needed to assess the influence of
| TABLE 1 Demographics and clinical features of asthmatic and nonasthmatic children with symptomatic COVID-19 |
|------------------------------------------------------|----------------|----------------|----------------|
| COVID−19 +                                            | Asthmatic patients | Nonasthmatic patients | p |
|                                                      | 8/50 (16%) | 42/50 (84%) |
| Demographic features                                  |                |                |    |
| Mean age (years)                                      | 10.9 ± 2.41 | 6.32 ± 5.77   | .001 |
| Sex (male)                                            | 6 (75%)   | 20 (47.6%)    | .25  |
| Rhinoconjunctivitis                                   | 6 (75%)   | 3 (7.1%)      | <.0001 |
| Food allergy                                          | 1 (12.5%) | 2 (4.76%)     | .414 |
| Allergic sensitization                                | 5 (62.5%) | 3 (7.1%)      | .001 |
| COVID-19 symptoms                                    |                |                |    |
| Respiratory symptoms\(^a\)                          | 8 (100%) | 23 (54.76%)  | .018 |
| Pneumonia                                            | 5 (62.5%) | 9 (21.42%)   | .215 |
| Fever                                                | 6 (75%)   | 27 (64.28%)  | .699 |
| Anosmia                                              | 1 (12.5%) | 4\(^b\) (13.79%) | >.99 |
| Ageusia                                              | 1 (12.5%) | 7\(^b\) (24.13%) | .391 |
| Gastrointestinal symptoms                            | 5 (62.5%) | 28 (66.67%)  | >.99 |
| Cutaneous symptoms                                    | 5 (62.5%) | 17 (40.47%)  | .277 |
| COVID-19 severity\(^c\)                              |                |                | .58 |
| Mild                                                  | 1/(12.5%) | 11/(26.2%)    | - |
| Moderate                                              | 5 (62.5%) | 21/(50%)     | - |
| Severe                                                | 2 (25%)   | 10/(23.8%)    | - |
| Management                                            |                |                |    |
| Inpatient                                             | 2/(25%)   | 18/(42.85%)   | .45 |
| PICU                                                  | 3/(37.5%) | 11/(26.19%)   | .67 |
| Medical discharge                                     | 3/(37.5%) | 13/(30.95%)   | .69 |
| Chest x-ray\(^d\)                                    | N = 8     | N = 21        | .215 |
| Abnormal                                              | 6 (75%)   | 9 (42.85%)    | - |
| Laboratory test                                       | N = 6     | N = 31        |    |
| Eosinopenia \((≤0.05 \times 10^9 \text{cells/L})\)  | 5 (83.33%)| 8 (25.80%)    | .014 |
| Total number of eosinophils \(\text{cells/\muL (median)}\) | 10 (IQR:0–88) | 130 (IQR: 40–310) | .008 |
| Recovery of the total number of eosinophils \(\text{median})\ | 90 (IQR: 40–90) | 140 (IQR: 60–225) | .007 |

Abbreviations: IQR, interquartile range; PICU, pediatric intensive care unit; SD, standard deviation.
\(^a\)Respiratory symptoms included dyspnea, cough, shortness of breath, and thoracic pain.
\(^b\)Anosmia and Ageusia were only measured in 29 nonasthmatic patients.
\(^c\)From reference 4, Qiu C, et al. Qiu classification for COVID-19 grade of severity: mild (low fever, mild cough, slight fatigue, and no evidence of pneumonia on imaging), moderate (fever and respiratory symptoms and evidence of pneumonia on imaging), severe (dyspnea, tachypnea, desaturation or radiologic worsening over 24–48 h) and critical (respiratory failure, septic shock, and/or multiple organ dysfunction).
\(^d\)Chest x-ray description made by a radiologist. Abnormalities: 5 pneumonia and 1 indeterminate (doubtful diffuse infiltrates).
### Clinical characteristics of asthmatic children with COVID-19 in a referral hospital

|                | Case 1 | Case 2 | Case 3 |
|----------------|--------|--------|--------|
| **Age (years)**| 12     | 12     | 10     |
| **Sex**        | Male   | Male   | Male   |
| **Allergy and asthma history** |        |        |        |
| Rhino conjunctivitis | No     | Yes    | Yes    |
| Food allergy | No      | No     | No     |
| Allergic sensitization | No     | No     | Pollen |
| Maintenance treatment | No     | Antileukotriene and ICS+LABA | INS and ICS |
| PRN treatment | SABA   | Ocular and oral antihistamine and SABA | Oral antihistamine and SABA |
| Rescue treatment for asthma exacerbations not related to COVID−19 | No | No | No |
| **Asthma management during COVID−19 pandemic** |        |        |        |
| Exacerbations | Yes | Yes | Yes |
| Rescue treatment | SABA PRN 7 days +ICS 7 days | SABA PRN 4 days | SABA PRN 7 days |
| Personal perception (2020 vs. 2019) | Worse | Worse | Same |
| **Symptoms of COVID−19 disease** |        |        |        |
| Respiratory | Cough | Pneumonia | Shortness of breath and thoracic pain |
| Gastrointestinal | Abdominal pain | No | No |
| Cutaneous | No | No | No |
| Fever | No | Yes | No |
| Anosmia | No | No | No |
| Ageusia | No | No | No |
| Grade of severity | Mild | Moderate | Moderate |
| **Hospitalization and treatment used** |        |        |        |
| Management | Home | Inpatient | Home |
| Nº of days of hospitalization | N/A | 3 | N/A |
| Oxygen therapy | N/A | Yes | N/A |
| Radiology findings | Normal | Unilateral pneumonia | Indeterminate (doubtful diffuse infiltrates) |
| Laboratory Findings | Not performed | Lymphopenia | Not performed |
| Eosinopenia | Elevated D dimer | Elevated LDH | |
| PCR not done | PCR not done | | |
| **Problems related to asthma disease due to COVID−19** |        |        |        |
| Asthma exacerbation | Asthma exacerbation | Asthma exacerbation |
| **Severity of asthma exacerbation based on GINA** |        |        |        |
| Mild | Mild | Mild |
| **Treatment after discharge** |        |        |        |
| ICS 1 week +SABA 7 days PRN | Continue its maintenance treatment +SABA 4 days PRN | Continue its maintenance treatment SABA 7 days PRN |
| **Recovery** | Complete | Complete | Complete |
| **Personal problems** |        |        |        |
| Of health care during the pandemic (not related to underlying allergic disease) | No | No | No |
| Respiratory sequelae after recovery | Not affected | Not affected | Exercise exacerbated asthma |

Abbreviations: ICS, inhaled corticosteroids; INS, intranasal steroids; IQR, interquartile range; LABA, long-acting beta agonist; N/A, non applicable; PICU, pediatric intensive care unit; PRN, pro re nata (treatment as needed); SABA, short-acting beta agonist; SCIT, subcutaneous immunotherapy; SD, standard deviation.

*Respiratory symptoms included dyspnea, cough, shortness of breath, and thoracic pain.

*From reference 4 Qiu C, et al.

*Chest x-ray description made by a radiologist.
### Clinical characteristics of asthmatic children with COVID-19 in a referral hospital

| Case | Age (years) | Sex | Allergy and asthma history | Maintenance treatment | PRN treatment | Rescue treatment for asthma exacerbations not related to COVID−19 | Asthma management during COVID−19 pandemic | Personal perception (2020 vs. 2019) | Symptoms of COVID−19 disease | Grade of severity | Hospitalization and treatment used | Problems related to asthma disease due to COVID−19 | Severity of asthma exacerbation based on GINA | Treatment after discharge | Recovery | Personal problems of healthcare during the pandemic (not related to underlying allergic disease) | Respiratory sequelae after recovery |
|------|-------------|-----|-----------------------------|-----------------------|---------------|---------------------------------------------------------------|------------------------------------------|---------------------------------------|-----------------------------|-----------------|----------------------------------|----------------------------------|-------------------------------------------|-----------------------------|--------------|---------------------------------------------------------------|-----------------------------|
| 1    | 12          | Male| Rhino conjunctivitis No     | No                    | SABA          | No                                                            | No                                       | Same                                  | Cough and shortness of breath | Mild            | PICU                             | Exercise exacerbate asthma | Mild                                      | SABA 7 days PRN               | Complete       | No                                                 | Not affected                |
| 2    | 12          | Male| Yes                          | Yes                   | Antileukotriene| No                                                            | No                                       | Same                                  | Vomiting and abdominal pain     | Moderate         | PICU                             | Exercise exacerbate asthma | Moderate                                  | SABA 7 days PRN               | Complete       | No                                                 | Not affected                |
| 3    | 10          | Male| No                           | No                    | No            | Yes                                                           | No                                       | Same                                  | No                           | Severe           | PICU                             | Exercise exacerbate asthma | Severe                              | SABA 7 days PRN               | Complete       | No                                                 | Not affected                |
| 4    | 15          | Female| Yes                          | Yes                   | SCIT          | No                                                            | No                                       | Same                                  | No                           | Severe           | PICU                             | Exercise exacerbate asthma | Moderate                                  | SABA 4–5 days in spring        | Complete       | No                                                 | Not affected                |
| 5    | 12          | Male| Yes                          | Yes                   | Antileukotriene| No                                                            | No                                       | Same                                  | No                           | Moderate         | PICU                             | Exercise exacerbate asthma | Moderate                                  | SABA 7 days PRN               | Complete       | No                                                 | Not affected                |
| 6    | 7           | Male| Yes                          | Yes                   | Antileukotriene| Yes                                                          | No                                       | Same                                  | Yes                          | Severe           | PICU                             | Exercise exacerbate asthma | Moderate                                  | SABA 7 days PRN               | Complete       | No                                                 | Not affected                |
| 7    | 10          | Female| No                           | No                    | No            | Yes                                                           | No                                       | Same                                  | No                           | Severe           | PICU                             | Exercise exacerbate asthma | Moderate                                  | SABA 7 days PRN               | Complete       | No                                                 | Not affected                |
| 8    | 9           | Male| No                           | No                    | No            | Yes                                                           | No                                       | Same                                  | No                           | Severe           | PICU                             | Exercise exacerbate asthma | Moderate                                  | SABA 7 days PRN               | Complete       | No                                                 | Not affected                |

**Abbreviations:** ICS, inhaled corticosteroids; INS, intranasal steroids; IQR, interquartile range; LABA, long-acting beta agonist; N/A, non-applicable; PICU, pediatric intensive care unit; PRN, pro re nata (treatment as needed); SABA, short-acting beta agonist; SCIT, subcutaneous immunotherapy; SD, standard deviation.

*Respiratory symptoms included dyspnea, cough, shortness of breath, and thoracic pain.*

*From reference 4 Qiu C, et al.*

*Chest x-ray description made by a radiologist.*
asthma and allergy in COVID-19 disease due to the low number of patients included in all series.

KEYWORDS
allergy, asthma, children, COVID-19, pediatric population

ACKNOWLEDGEMENTS
None.

CONFLICT OF INTEREST
All authors declare no conflict on interests related to this manuscript.

FUNDING INFORMATION
None.

AUTHOR CONTRIBUTION
Irene Bartha: Conceptualization (lead); Data curation (lead); Formal analysis (lead); Investigation (lead); Methodology (lead); Project administration (lead); Supervision (lead); Validation (lead); Visualization (lead); Writing – original draft (lead); Writing – review & editing (lead).

Marta Bernaola: Conceptualization (lead); Data curation (lead); Formal analysis (lead); Investigation (lead); Methodology (lead); Project administration (lead); Supervision (lead); Validation (lead); Visualization (lead); Writing – original draft (lead); Writing – review & editing (lead).

Carmelo Escudero: Conceptualization (supporting); Data curation (equal); Formal analysis (supporting); Investigation (supporting); Methodology (equal); Project administration (equal); Supervision (equal); Validation (equal); Visualization (equal); Writing – original draft (equal); Writing – review & editing (equal).

Pablo Rodríguez del Río: Conceptualization (supporting).

Raphaëlle Bazire: Conceptualization (supporting).

Maria Dolores Ibáñez: Conceptualization (equal); Data curation (equal); Formal analysis (equal); Investigation (equal); Methodology (equal); Project administration (lead); Supervision (lead); Validation (lead); Writing – original draft (equal); Writing – review & editing (lead).

Correspondence
Maria Dolores Ibáñez Sandín, Allergy Department, Hospital Infantil Universitario Niño Jesús, Avda/ Menéndez Pelayo, Nº 65. 28009 Madrid, Spain.
Email: mibanezs@salud.madrid.org

Irene Bartha and Marta Bernaola contributed equally as first authors.

ORCID
Irene Bartha  https://orcid.org/0000-0002-3444-4131
Marta Bernaola  https://orcid.org/0000-0003-4199-573X
Carmelo Escudero  https://orcid.org/0000-0003-2157-8699
Pablo Rodríguez del Río  https://orcid.org/0000-0002-0783-1988
Raphaëlle Bazire  https://orcid.org/0000-0003-0079-3613
Maria Dolores Ibáñez Sandín  https://orcid.org/0000-0001-8291-5121

REFERENCES
1. Informe sobre la situación de COVID-19 en España. Red Nacional de Vigilancia Epidemiológica. https://www.isciii.es/Paginas/Inicio.aspx. Accessed January 22, 2021.
2. Licari A, Votto M, Brambilla I, et al. Allergy and asthma in children and adolescents during the COVID outbreak: what we know and how we could prevent allergy and asthma flares. Allergy. 2020;75(9):2402-2405.
3. Jackson DJ, Busse WW, Bacharier LB, et al. Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor, ACE2. J Allergy Clin Immunol. 2020;146(1):203-206.
4. Qiu C, Cui C, Hautefort C, et al. Olfactory and gustatory dysfunction as an early identifier of COVID-19 in adults and children: an international multicenter study. Otolaryngol Head Neck Surgery. 2020;163(4):714-721.
5. Brough HA, Kalayci O, Sediva A, et al. Managing childhood allergies and immunodeficiencies during respiratory virus epidemics - The 2020 COVID-19 pandemic: a statement from the EAACI-section on pediatrics. Pediatr Allergy Immunol. 2020;31(5):442-448.
6. Du H, Dong X, Zhang JJ, et al. Clinical characteristics of 182 pediatric COVID-19 patients with different severities and allergic status. Allergy. 2020;76(2):510-532.
7. Barroso B, Valverde-Monge M, Cañas Jose A, et al. Presenting prevalence, characteristics and outcome of asthmatic patients with T2 diseases in hospitalized subjects with COVID-19 in Madrid, Spain. J Investig Allergol Clin Immunol. 2020;30(5):382-384.
8. Castro-Rodriguez JA, Forno E. Asthma and COVID-19 in children: a systematic review and call for data. Pediatr Pulmonol. 2020;55(12):3573-3578.
10. Papadopoulos NG, Custovic A, Deschildre A, et al. Impact of COVID-19 on pediatric asthma: practice adjustments and disease burden. *J Allergy Clin Immunol Pract*. 2020;8(8):2592-2599.

11. Ruano FJ, Somoza Álvarez ML, Haroun-Díaz E, et al. Impact of the COVID-19 pandemic in children with allergic asthma. *J Allergy Clin Immunol Pract*. 2020;8(9):3172-3174.

12. Lindsley AW, Schwartz JT, Rothenberg ME. Eosinophil responses during COVID-19 infections and coronavirus vaccination. *J Allergy Clin Immunol*. 2020;146(1):1-7.

13. Valverde-Monge M, Cañas JA, Barroso B, et al. Eosinophils and chronic respiratory diseases in hospitalized COVID-19 patients. *Front Immunol*. 2021;2(12):1-10.